Health care stocks were easing Monday afternoon, with the NYSE Health Care Index down 0.2% and the Health Care Select Sector SPDR Fund (XLV) shedding 0.3%.
The iShares Biotechnology ETF (IBB) rose 0.1%.
In corporate news, PTC Therapeutics (PTCT) signed a licensing deal with Novartis (NVS) unit Novartis Pharmaceuticals worth up to $2.9 billion for PTC518, its candidate treatment for Huntington's disease. PTC shares jumped 18% and Novartis was down 0.9%.
Senti Biosciences (SNTI) shares soared 469%. The company said Monday that two of three acute myeloid leukemia patients treated with its Senti-202 investigational cell therapy for blood cancers achieved complete remission in a phase 1 trial.
Gelteq (GELS) shares surged 28% after it said Monday its largest client in the US, Healthy Extracts, has increased its order of the company's collagen and Mynus sugar blocker gels by 50%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。